HIV, HTLV AND DRUG ABUSE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。HIV/HTLV合并感染经常发生，在HIV-1感染者中占1-15%。然而，HTLV-1/2病毒负荷水平与疾病以及抗逆转录病毒治疗效果之间的关系尚不清楚。来自路易斯安那州新奥尔良HIV门诊（HOP）的HTLV-1/2 elisa阳性个体（N=97）在基线入组时被评估为随访研究。考虑的变量包括：人口统计学、街头毒品的使用、抗逆转录病毒治疗、T细胞亚群、HIV病毒载量、HTLV-1/2 Western blotting、用于检测HTLV-1/2 p19抗原的外周血单个核细胞（PBMC）培养，以及用于量化HTLV-1/2前病毒拷贝数的实时PCR。HTLV前病毒载量分为？2万个和2万个类别，便于比较。CD4和CD8被分为三个有序的类别，使用确定的切点。计算频率，并使用卡方统计量或Fisher¿s Exact检验来检验组间差异。采用双侧假设检验，采用SAS 8.2版本进行统计分析。在HTLV western blot验证试验阳性的受试者中，HTLV-1/2前病毒拷贝数为20,000拷贝/106 PBMCs与CD4细胞绝对计数较高、HTLV-1与HTLV-2 western blot阳性、HTLV-1/2 p19阳性检测结果具有统计学意义。初步数据分析显示，在过去3个月内，在种族、性别、抗逆转录病毒药物的使用或街头毒品的使用方面没有差异。这些结果表明，pbmc中HTLV-1/2病毒负荷对hiv感染者的疾病分期有影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV/HTLV co-infections occur frequently and in the range of 1-15% among HIV-1 infected individuals. The relationship between levels of HTLV-1/2 viral burden and disease, and effects of antiretroviral treatment, however, is unknown. HTLV-1/2 ELISA-positive individuals (N=97) from the New Orleans, Louisiana, HIV Outpatient Clinic (HOP) were evaluated at baseline enrollment into a follow-up study. Variables considered were: demographics, use of street drugs, antiretroviral therapy, T cell subsets, HIV viral loads, HTLV-1/2 Western blotting, peripheral blood mononuclear cell (PBMC) cultures for detection of HTLV-1/2 p19 antigens, and real time PCR to quantify HTLV-1/2 proviral copy number. HTLV proviral load was dichotomized into ? 20,000 and 20,000 categories for ease of comparison. CD4 and CD8 were categorized into three ordinal categories, using well-established cut-points. Frequencies were computed and Chi-squared statistics or Fisher¿s Exact test were used to test for differences between groups. Hypothesis tests were two-sided and SAS version 8.2 was used to conduct statistical analysis. Among those subjects with a positive HTLV western blot confirmatory test, there was a statistically significant correlation between an HTLV-1/2 proviral copy number of 20,000 copies/106 PBMCs and a higher absolute CD4 cell count, HTLV-1 vs HTLV-2 western blot positivity, and a HTLV-1/2 p19 positive assay result. Preliminary data analysis suggested no differences with respect to race, gender, antiretroviral drug administration, or use of street drugs within the prior 3 months. These results suggest that HTLV-1/2 viral burden in PBMCs has an impact on disease staging among HIV-infected individuals.